United States-based Parnell Pharmaceuticals has announced that it has developed Nomovid, claimed to be the first antiviral nasal spray in the United States, it was reported on Wednesday.
The company says that the product is easy-to-use, low-cost and can be offered over-the-counter for consumers.
The product is based on a substance licensed by the company from New Mexico Tech University to treat drug-resistant bacteria and fungi such as MRSA and Candida auris. Parnell had been taking the necessary steps to enter the FDA approval process for the MRSA indication, until it reportedly saw very positive results against COVID-19. The company is now filing for the COVID-19 indication instead.
Novartis secures European approval for remibrutinib in chronic spontaneous urticaria
Evofem signs exclusive deal to expand SOLOSEC distribution in sub-Saharan Africa
GSK secures US and EU fast-track designations for efimosfermin in MASH
AstraZeneca secures US approval for Saphnelo self-administration in lupus treatment
Abbott presents late-breaking clinical data on treating heart rhythm disorders
Novartis receives positive CHMP opinion for Itvisma in spinal muscular atrophy
Servier completes Day One Biopharmaceuticals acquisition
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
WuXi Biologics gains MFDS approval for three Wuxi manufacturing sites